Halobetasol Propionate Cas 66852-54-8

Halobetasol Propionate (CAS 66852-54-8): Comprehensive User Guide

Table of Contents

• 1. Product Overview & Specifications
• 2. Applications & Therapeutic Uses
• 3. Usage Guidelines & Safety Protocols
• 4. Comparative Analysis with Similar Corticosteroids
• 5. Industry Case Studies
• 6. Client Success Stories
• 7. Contact for Customized Solutions

1. Product Overview & Specifications

2. Applications & Therapeutic Uses

Primary Medical Applications:

• Treatment of corticosteroid-responsive dermatoses (e.g., psoriasis, eczema)
• Management of inflammatory skin conditions resistant to lower-potency steroids
• Off-label use in lichen planus and discoid lupus erythematosus

Mechanism of Action: Potent glucocorticoid receptor agonist inhibiting inflammatory mediators (prostaglandins, leukotrienes) and reducing lymphocyte proliferation.

3. Usage Guidelines & Safety Protocols

Recommended Dosage:

• Topical application: 0.05% cream/ointment once daily (max 50g/week)
• Treatment duration: ≤2 weeks for most patients

Key Precautions:

• Contraindicated in rosacea, acne, and perioral dermatitis
• Monitor for HPA axis suppression in prolonged use

4. Comparative Analysis with Similar Corticosteroids

5. Industry Case Studies

Case Study 1: Psoriasis Management in Climate-Challenged Regions
A Southeast Asian pharmaceutical company achieved 89% improvement in psoriatic plaque clearance using our halobetasol formulation in high-humidity conditions.

Case Study 2: Pediatric Eczema Formulation
European dermatology researchers developed a low-irritant halobetasol emulsion for children aged 6-12, maintaining efficacy while reducing TEWL by 42%.

6. Client Success Stories

Client A: Top 10 Global Pharma Company
– Requirement: Stable 0.05% cream formulation for tropical markets
– Our Solution: Developed humidity-resistant base with 36-month shelf life
– Outcome: 17% market share gain in first year

Client B: US Dermatology Startup
– Challenge: Minimize systemic absorption in elderly patients
– Our Innovation: Liposomal delivery system reducing absorption to 0.8%
– FDA Approval: Obtained in 14 months

7. Contact for Customized Solutions

For formulation support, bulk orders, or clinical trial materials:

• Email: info@vivalr.com
• Phone: (86) 15866781826

Request a free sample or technical dossier: [Submit inquiry form]